Skip Standard Navigation Links
Centers for Disease Control and Prevention
 CDC Home Search Health Topics A-Z
peer-reviewed.gif (582 bytes)
eid_header.gif (2942 bytes)
Past Issue

Vol. 12, No. 2
February 2006

Adobe Acrobat logo

EID Home | Ahead of Print | Past Issues | EID Search | Contact Us | Announcements | Suggested Citation | Submit Manuscript

PDF Version | Comments Comments | Email this article Email this article



References
Table

Letter

Borrelia burgdorferi and Anaplasma phagocytophilum Coinfection

Micha Loebermann,* Volker Fingerle,† Matthias Lademann,* Carlos Fritzsche,* and Emil C. Reisinger*Comments
*University of Rostock Medical School, Rostock, Germany; and †Ludwig-Maximilian-Universität München, Munich, Germany

Suggested citation for this article


To the Editor: In central Europe, Anaplasma phagocytophilum and Borrelia burgdorferi are transmitted by the hard tick Ixodes ricinus (1). Acute human granulocytic ehrlichiosis (HGE) caused by A. phagocytophilum has rarely been documented in Europe (2). Typical symptoms include fever, headache, myalgia, leukopenia, thrombocytopenia, and abnormal liver function test results. The serologic prevalence ranges from 1.9% to 14% in Germany (1), while clinically apparent infections of HGE have not been reported.

Acute Lyme borreliosis in Europe is associated with erythema migrans (3), recognized in up to 90% of patients (4). Erythema migrans may be accompanied by systemic symptoms such as fever, fatigue, myalgia, arthralgia, headache, or stiff neck (3,4). In southern Germany, an incidence of 111 per 100,000 inhabitants has been reported (4).

A 60-year-old woman from northern Germany was admitted with temperature of <40°C, headache, myalgia, and generalized weakness that had begun 6 days earlier. She had noticed an erythema migrans on her right thigh 4 days before she sought treatment. At admission, a tender, 5 × 8 cm rash and a central papule were seen, but without central clearing. The clinical examination was otherwise normal. Three weeks earlier she had been on a trekking tour in Austria and Slovenia but had not been aware of any tick bites.

The leukocyte count was 3,030/μL (normal 4,000–9,000), with 65% neutrophils, 24% lymphocytes, 10% monocytes, and 1% lymphoid cells. The following results were observed: platelets 127,000/μL (normal 150,000–450,000), aspartate aminotransferase 108 U/L (normal <31), alanine aminotransferase 154 U/L (normal <34), gamma-glutamyl transferase 98 U/L (normal <38), lactate dehydrogenase 317 U/L (normal <247), alkaline phosphatase 314 U/L (normal <237), direct bilirubin 4.7 μmol/L (normal <3.4), C-reactive protein 132 mg/L (normal <5), and neopterin 30 nmol/L (normal <10). All other routine laboratory parameters were normal.

May-Grünwald-Giemsa (Fluke, Neu Ulm, Germany)–stained whole-blood smears did not show Anaplasma initially and during follow-up. On admission serum antibody tests were negative for A. phagocytophilum, B. burgdorferi, hepatitis A, B, and C, human herpes virus 6, herpes simplex virus 1 and 2, Epstein-Barr virus, cytomegalovirus, and tickborne encephalitis virus. Because Lyme borreliosis and possible HGE were suspected, the patient was treated with oral doxycycline 200 mg once daily for 3 weeks. Within 4 days after initiation of treatment, the patient recovered completely; thrombocytes and leukocytes had normalized. Liver enzyme levels were still elevated but had normalized at a follow-up examination 28 days later.

Four days after the initial examination, results for Borrelia-specific immunoglobulin M (IgM) antibodies were positive, while results for IgG antibodies remained negative (Table). Four weeks after the onset of symptoms, a test for A. phagocytophilum–specific IgM antibodies was positive and IgG was negative thereafter (Table). An initial EDTA blood sample that was stored frozen and examined retrospectively as well as follow-up EDTA blood samples were negative for A. phagocytophilum in a polymerase chain reaction (PCR) assay.

One year after initial examination, results for Borrelia-specific IgM antibodies were positive and results for A. phagocytophilum-specific antibodies were negative (Table). Although HGE has not been reported in Germany, a coinfection with B. burgdorferi and A. phagocytophilum should be considered in patients with erythema migrans and atypical changes for Lyme borreliosis such as fever, leukopenia, thrombocytopenia, and elevated liver function test results.

The patient had traveled to an area where both tickborne pathogens, A. phagocytophilum and B. burgdorferi, were endemic. Erythema migrans and antibody follow up suggested Lyme borreliosis. High fever, leukopenia, thrombocytopenia, and elevated liver enzyme levels indicated HGE. Anaplasma PCR was negative, possibly because blood samples were tested retrospectively after 3 months of storage at –20°C. However, a commercially available indirect fluorescent antibody assay was able to demonstrate seroconversion of HGE-specific IgM antibodies 1 month after the initial onset of symptoms. According to manufacturer's information, specificity ranged from 97.5% to 100%; sensitivity was 71.4% at 60 days after A. phagocytophilum infection. A. phagocytophilum IgG antibodies were not detected during follow-up, likely because of prompt treatment with doxycycline.

Wormser et al. (5) suggested that Borrelia-specific antibodies might indicate false-positive results in patients with HGE infection. Our case, however, meets criteria of a newly acquired infection with B. burgdorferi sensu lato, with an erythema migrans and seroconversion of Borrelia-specific IgM antibodies.

References

  1. Fingerle V, Goodman JL, Johnson RC, Kurtti TJ, Munderloh UG, Wilske B. Human granulocytic ehrlichiosis in southern Germany: Increased seroprevalence in high-risk groups. J Clin Microbiol. 1997;35:3244–7.
  2. Lotric-Furlan S, Petrovec M, Avsic-Zupanc T, Nicholson WL, Sumner JW, Childs JE, et al. Prospective assessment of the etiology of acute febrile illness after a tick bite in Slovenia. Clin Infect Dis. 2001;33:503–10.
  3. Weber K, Neupert U, Büchner SA. Erythema migrans and early signs and symptoms. In: Weber K, Burgdorfer W, editors. Aspects of Lyme borreliosis. Berlin: Springer; 1993. p.105–22.
  4. Huppertz HI, Böhme M, Standaert SM, Karch H, Plotkin SA. Incidence of Lyme borreliosis in the Würzburg region of Germany. Eur J Clin Microbiol Infect Dis. 1999;18:697–703.
  5. Wormser GP, Horowitz HW, Dumer JS, Schwartz I, Aguero-Rosenfeld M. False-positive Lyme disease serology in human granulocytic ehrlichiosis. Lancet. 1996;347:981–2.

 

Table. Results of serologic tests at diagnosis and during follow-up*


Time (d) after onset of symptoms

Anaplasma (Ehrlichia) phagocytophilum (IFA)†

Borrelia burgdorferi (ELISA)‡

Borrelia burgdorferi (Immunoblot)§




IgM

IgG

IgM

IgG

IgM

IgG


6

Negative (<1:20)

Negative (<1:32)

Negative

Negative

Negative

Negative

10

ND

ND

Positive

Negative

ND

ND

28

Positive (1:40)

Negative (1:32)

Positive

Negative

Positive

Negative

107

Positive (1:20)

Negative (<1:32)

Positive

Negative

Positive

Negative

380

Negative (<1:20)

Negative (<1:32)

Equivocal

Negative

Positive

Negative


*Symptoms (fever, headache, myalgia) started 6 days before presentation. IFA, immunofluorescent assay; ELISA, enzyme-linked immunosorbent assay; Ig, immunoglobulin; ND, not done.

†Genzyme Virotech, Germany. Positive titers: IgM >1:20, IgG >1:64.

‡Behring, Germany.

§In-house Immunoblot, Max von Pettenkofer-Institut, Munich, Germany.

 

Suggested citation for this article:
Loebermann M, Fingerle V, Lademann M, Fritzsche C, Reisinger EC. Borrelia burgdorferi and Anaplasma phagocytophilum coinfection [letter]. Emerg Infect Dis [serial on the Internet]. 2006 Feb [date cited]. Available from http://www.cdc.gov/ncidod/EID/vol12no02/05-0765.htm

   
     
   
Comments to the Authors

Please use the form below to submit correspondence to the authors or contact them at the following address:

Emil C. Reisinger, Division for Tropical Medicine and Infectious Diseases, Department of Medicine, University of Rostock Medical School, Ernst-Heydemann-Str 6, D-18057 Rostock, Germany; fax: 49-381-494-7509; email: emil.reisinger@medizin.uni-rostock.de

Please note: To prevent email errors, please use no web addresses, email addresses, HTML code, or the characters <, >, and @ in the body of your message.

Return email address optional:


 


Comments to the EID Editors
Please contact the EID Editors at eideditor@cdc.gov

Email this article

Please note: To prevent email errors, please use no web addresses, email addresses, HTML code, or the characters <, >, and @ in the body of your message.

Your email:

Your friend's email:

Message (optional):

 

 

 

EID Home | Top of Page | Ahead-of-Print | Past Issues | Suggested Citation | EID Search | Contact Us | Accessibility | Privacy Policy Notice | CDC Home | CDC Search | Health Topics A-Z

This page posted January 23, 2006
This page last reviewed January 26, 2006

Emerging Infectious Diseases Journal
National Center for Infectious Diseases
Centers for Disease Control and Prevention